Recurrent Endometrial Dedifferentiated Carcinoma
1 clinical trials · Condition
◉ Watch Recurrent Endometrial Dedifferentiated Carcinoma
| Record | Firm | Date |
|---|---|---|
| Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer (NCT03914612) | National Cancer Institute (NCI) | 2019-08-22 |
Track Recurrent Endometrial Dedifferentiated Carcinoma automatically
Every clearance here is in the API, with alerts when new ones post.